TAU targets drug-resistant ovarian tumors with nanotechnology
Ovarian cancer accounts for more deaths of American women than any other cancer of the female reproductive system. According to the American Cancer Society, one in 72 American women will be diagnosed with ovarian cancer, and one in 100 will ultimately die of the condition.
Now Prof. Dan Peer of Tel Aviv University‘s Department of Cell Research and Immunology has proposed a new strategy to tackle an aggressive subtype of ovarian cancer using a new nanoscale drug-delivery system designed to target specific cancer cells. He and his team — Keren Cohen and Rafi Emmanuel from Peer’s Laboratory of Nanomedicine and Einat Kisin-Finfer and Doron Shabbat, from TAU’s Department of Chemistry — have devised a cluster of nanoparticles called gagomers, made of fats and coated with a kind of polysugar. When filled with chemotherapy drugs, these clusters accumulate in tumors, producing dramatically therapeutic benefits.
The objective of Peer’s research is two-fold: to provide a specific target for anti-cancer drugs to increase their therapeutic benefits, and to reduce the toxic side effects of anti-cancer therapies. The study was published in February in the journal ACS Nano.
Why chemotherapy fails
According to Prof. Peer, traditional courses of chemotherapy are not an effective line of attack. Chemotherapy’s failing lies in the inability of the medicine to be absorbed and maintained within the tumor cell long enough to destroy it. In most cases, the chemotherapy drug is almost immediately ejected by the cancer cell, severely damaging the healthy organs that surround it, leaving the tumor cell intact.
But with their new therapy, Peer and his colleagues saw a 25-fold increase in tumor-accumulated medication and a dramatic dip in toxic accumulation in healthy organs. Tested on laboratory mice, the gagomer mechanism effects a change in drug-resistant tumor cells. Receptors on tumor cells recognize the sugar that encases the gagomer, allowing the binding gagomer to slowly release tiny particles of chemotherapy into the cancerous cell. As more and more drugs accumulate within the tumor cell, the cancer cells begin to die off within 24-48 hours.
“Tumors become resistant very quickly. Following the first, second, and third courses of chemotherapy, the tumors start pumping drugs out of the cells as a survival mechanism,” said Prof. Peer. “Most patients with tumor cells beyond the ovaries relapse and ultimately die due to the development of drug resistance. We wanted to create a safe drug-delivery system, which wouldn’t harm the body’s immune system or organs.”
The Latest on: Ovarian cancer
[google_news title=”” keyword=”Ovarian cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Ovarian cancer
- N.Y. woman clears $108M of other people's medical debt — after dying of canceron November 29, 2023 at 2:49 pm
New York book publisher Casey McIntyre's health insurance allowed her to receive cancer care without saddling her family in medical debt. But as she navigated the health-care system, she met other ...
- How to support NormaLeah Ovarian Cancer Initiativeon November 29, 2023 at 11:02 am
DAVENPORT, Iowa (KWQC) -It was a little over eleven years ago that Paula underwent her final round of chemotherapy in Iowa City for her treatment to beat ovarian cancer. Ever since, she has had a ...
- After ovarian cancer diagnosis, an Oakland dancer is raising awarenesson November 28, 2023 at 8:59 am
Nina Schnall has been fighting ovarian cancer since 2020 and says there should be more conversation around the deadliest reproductive disease.
- Ovarian Cancer Drugs Market Size Worth USD 5.35 Billion in 2032 | Emergen Researchon November 28, 2023 at 8:00 am
Technological advancements and development in cancer treatment, extensive & Development (R&D) in novel drug therapeutics, and increasing use of different combination therapies for treatment of ovarian ...
- Woman, 25, with ovarian cancer recalls symptoms that doctors dismissed: 'You’re fine'on November 28, 2023 at 7:46 am
A 25-year-old woman had pain in her side as a symptom of stage 2 low-grade serous ovarian cancer. She had a tumor on her ovary. Doctors said she was fine.
- 25-Year-Old with Ovarian Cancer Reveals Symptoms Dismissed by Doctorson November 27, 2023 at 6:08 pm
"I blacked out for most of the conversation," Emma Schlamm said of the moment she learned she had ovarian cancer ...
- Ovarian Cancer: Discovery Of Prospective Drug Targetson November 27, 2023 at 3:13 pm
The survival rate for ovarian cancer is not very high, as it is often diagnosed at a late stage. Surgery and systemic chemotherapy can help improve the survival rate, but only to a certain extent.
- Ovarian Cancer Warning Signs: What To Look Out Foron November 27, 2023 at 1:28 pm
Overview Cancer that arises from different cells of the ovaries, the paried female reproductive organ. Symptoms If you or someone you know is exhibiting symptoms of a Ovarian cancer, seek medical ...
- Scientists discover potent and selective inhibitors for ovarian cancer treatmenton November 24, 2023 at 6:44 am
To identify potential therapeutic targets and preclinical drug candidates for the treatment of ovarian cancer, researchers led by Tan Li from the Shanghai Institute of Organic Chemistry of the Chinese ...
- Bay Area ovarian cancer foundation carries on founding member’s legacy to shine light on silent killeron November 22, 2023 at 4:03 pm
One of the mottos of the Celma Mastry Ovarian Cancer Foundation is "one step closer to the cure" and it has taken many steps over the past 20 years to achieve that goal.
via Bing News